Avastin is one of 685 small molecule programs targeting Proliferative Diabetic Retinopathy. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
2828 competitors in Breast Cancer
Avastin
Halaven
Megace
Cymbalta
MS Contin
Blenoxane
Lexiscan
Adenocard
Effexor
Spravato
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Sources